Niemann-Pick disease, type C1 (NPC1), is a rare, fatal neurodegenerative disorder caused by pathological variations in NPC1. We and others have previously demonstrated the efficacy of systemic adeno-associated virus (AAV) gene therapy with AAV9 in murine models of NPC1. The presence of neutralizing antibodies (NAbs) caused by natural exposure to wildtype AAVs may impair AAV transduction efficacy and reduce or negate the benefit of gene therapy. In addition, there remains the question of whether individuals seroconvert with age and whether seroconversion limits the window of therapeutic efficacy. Thus, we assessed the prevalence of anti-AAV9 and anti-AAV2 NAbs in serum samples from 22 individuals with NPC1 at two different time points: one closer to diagnosis (0.9–17 years old) and another collected between 4 and 15 years later during follow-up (6–28 years old). At a titer of <1:5, we found that more than half of the cohort lacked NAbs against either AAV2 (68.2%) or AAV9 (59.1% at time 1, 63.6% at time 2). Notably, only 3 out of 22 individuals showed a transition from undetectable to detectable NAb titers, and most participants maintained stable titers over time, unaffected by age. These data support the feasibility of systemic or direct CNS AAV9 gene therapy in this patient population.
VanierMT. Niemann-Pick disease type C. Orphanet J Rare Dis, 2010; 5:16; doi: 10.1186/1750-1172-5-16
3.
PattersonMC, HendrikszCJ, WalterfangM, et al.;NP-C Guidelines Working Group. Recommendations for the diagnosis and management of Niemann-Pick disease type C: An update. Mol Genet Metab, 2012; 106(3):330–344; doi: 10.1016/j.ymgme.2012.03.012
4.
OryDS. Niemann-Pick type C: A disorder of cellular cholesterol trafficking. Biochim Biophys Acta, 2000; 1529(1–3):331–339; doi: 10.1016/s1388-1981(00)00158-x
5.
MullardA. FDA approves first two drugs for rare Niemann-Pick disease. Nat Rev Drug Discov, 2024; 23(11):804; doi: 10.1038/d41573-024-00162-9
6.
PattersonMC, MengelE, VanierMT, et al.;NPC Registry investigators. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: An observational cohort study. Orphanet J Rare Dis, 2015; 10:65; doi: 10.1186/s13023-015-0284-z
7.
FieldsT, BremovaTM, BillingtonI, et al.N-acetyl-L-leucine for Niemann-Pick type C: A multinational double-blind randomized placebo-controlled crossover study. Trials, 2023; 24(1):361; doi: 10.1186/s13063-023-07399-6
8.
MengelE, PattersonMC, Da RiolRM, et al.Efficacy and safety of arimoclomol in Niemann-Pick disease type C: Results from a double-blind, randomised, placebo-controlled, multinational phase 2/3 trial of a novel treatment. J Inherit Metab Dis, 2021; 44(6):1463–1480; doi: 10.1002/jimd.12428
9.
OryDS, OttingerEA, FarhatNY, et al.Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: A non-randomised, open-label, phase 1-2 trial. Lancet, 2017; 390(10104):1758–1768; doi: 10.1016/S0140-6736(17)31465-4
10.
SolomonBI, SmithAC, SinaiiN, et al.Association of Miglustat with swallowing outcomes in Niemann-Pick Disease, Type C1. JAMA Neurol, 2020; 77(12):1564–1568; doi: 10.1001/jamaneurol.2020.3241
11.
PattersonMC, GarverWS, GiuglianiR, et al.Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study. J Inherit Metab Dis, 2020; 43(5):1060–1069; doi: 10.1002/jimd.12245
12.
SharmaR, HastingsC, Staretz-ChachamO, et al.Long-term administration of intravenous Trappsol® Cyclo™ (HP-β-CD) results in clinical benefits and stabilization or slowing of disease progression in patients with Niemann-Pick disease type C1: Results of an international 48-week Phase I/II trial. Mol Genet Metab Rep, 2023; 36:100988; doi: 10.1016/j.ymgmr.2023.100988
13.
HudryE, VandenbergheLH. Therapeutic AAV gene transfer to the nervous system: A clinical reality. Neuron, 2019; 102(1):263; doi: 10.1016/j.neuron.2019.03.020
Al-ZaidyS, PickardAS, KothaK, et al.Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol, 2019; 54(2):179–185; doi: 10.1002/ppul.24203
16.
DayJW, FinkelRS, MercuriE, et al.Adeno-associated virus serotype 9 antibodies in patients screened for treatment with onasemnogene abeparvovec. Mol Ther Methods Clin Dev, 2021; 21:76–82; doi: 10.1016/j.omtm.2021.02.014
17.
FuH, MeadowsAS, PinedaRJ, et al.Differential prevalence of antibodies against adeno-associated virus in healthy children and patients with mucopolysaccharidosis III: Perspective for AAV-Mediated Gene Therapy. Hum Gene Ther Clin Dev, 2017; 28(4):187–196; doi: 10.1089/humc.2017.109
18.
BevanAK, DuqueS, FoustKD, et al.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 2011; 19(11):1971–1980; doi: 10.1038/mt.2011.157
19.
SamaranchL, SalegioEA, San SebastianW, et al.Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther, 2012; 23(4):382–389; doi: 10.1089/hum.2011.200
20.
SaraivaJ, NobreRJ, Pereira de AlmeidaL. Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. J Control Release, 2016; 241:94–109; doi: 10.1016/j.jconrel.2016.09.011
21.
LykkenEA, ShyngC, EdwardsRJ, et al.Recent progress and considerations for AAV gene therapies targeting the central nervous system. J Neurodev Disord, 2018; 10(1):16; doi: 10.1186/s11689-018-9234-0
22.
KantorB, BaileyRM, WimberlyK, et al.Methods for gene transfer to the central nervous system. Adv Genet, 2014; 87:125–197; doi: 10.1016/B978-0-12-800149-3.00003-2
23.
KurokawaY, OsakaH, KougaT, et al.Gene therapy in a mouse model of Niemann-Pick disease type C1. Hum Gene Ther, 2021; 32(11–12):589–598; doi: 10.1089/hum.2020.175
24.
HughesMP, SmithDA, MorrisL, et al.AAV9 intracerebroventricular gene therapy improves lifespan, locomotor function and pathology in a mouse model of Niemann-Pick type C1 disease. Hum Mol Genet, 2018; 27(17):3079–3098; doi: 10.1093/hmg/ddy212
25.
HughesMP, NelvagalHR, Coombe-TennantO, et al.A novel small NPC1 promoter enhances AAV-mediated gene therapy in mouse models of Niemann-Pick type C1 disease. Cells, 2023; 12(12):1619; doi: 10.3390/cells12121619
26.
ChandlerRJ, WilliamsIM, GibsonAL, et al.Systemic AAV9 gene therapy improves the lifespan of mice with Niemann-Pick disease, type C1. Hum Mol Genet, 2017; 26(1):52–64; doi: 10.1093/hmg/ddw367
27.
DavidsonCD, GibsonAL, GuT, et al.Improved systemic AAV gene therapy with a neurotrophic capsid in Niemann-Pick disease type C1 mice. Life Sci Alliance, 2021; 4(10):e202101040; doi: 10.26508/lsa.202101040
28.
ColellaP, RonzittiG, MingozziF. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev, 2018; 8:87–104; doi: 10.1016/j.omtm.2017.11.007
29.
GraySJ, MatagneV, BachaboinaL, et al.Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates. Mol Ther, 2011; 19(6):1058–1069; doi: 10.1038/mt.2011.72
30.
StolteB, Schreiber-KatzO, GüntherR, et al.Prevalence of anti-adeno-associated virus serotype 9 antibodies in adult patients with spinal muscular atrophy. Hum Gene Ther, 2022; 33(17–18):968–976; doi: 10.1089/hum.2022.054
31.
FitzpatrickZ, LeborgneC, BarbonE, et al.Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV Vector transduction. Mol Ther Methods Clin Dev, 2018; 9:119–129; doi: 10.1016/j.omtm.2018.02.003
32.
ErlesK, SebKovP, SchlehoferJR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol, 1999; 59(3):406–411; doi: 10.1002/(SICI)1096-9071(199911)59:3<406::AID-JMV22>3.0.CO;2-N
33.
CalcedoR, MorizonoH, WangL, et al.Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol, 2011; 18(9):1586–1588; doi: 10.1128/CVI.05107-11
34.
KlamrothR, HayesG, AndreevaT, et al.Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A. Hum Gene Ther, 2022; 33(7–8):432–441; doi: 10.1089/hum.2021.287
35.
CalcedoR, VandenbergheLH, GaoG, et al.Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis, 2009; 199(3):381–390; doi: 10.1086/595830
36.
BoutinS, MonteilhetV, VeronP, et al.Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors. Hum Gene Ther, 2010; 21(6):704–712; doi: 10.1089/hum.2009.182
37.
MimuroJ, MizukamiH, ShimaM, et al.The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals. J Med Virol, 2014; 86(11):1990–1997; doi: 10.1002/jmv.23818
38.
LiC, NarkbunnamN, SamulskiRJ, et al.;Joint Outcome Study Investigators. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther, 2012; 19(3):288–294; doi: 10.1038/gt.2011.90
HarringtonEA, SloanJL, ManoliI, et al.Neutralizing antibodies against adeno-associated viral capsids in patients with mut Methylmalonic Acidemia. Hum Gene Ther, 2016; 27(5):345–353; doi: 10.1089/hum.2015.092
41.
Bharucha-GoebelDX, ToddJJ, SaadeD, et al.;GAN Trial Team. Intrathecal gene therapy for giant axonal neuropathy. N Engl J Med, 2024; 390(12):1092–1104; doi: 10.1056/NEJMoa2307952
42.
CalcedoR, FrancoJ, QinQ, et al.Preexisting neutralizing antibodies to adeno-associated virus capsids in large animals other than monkeys may confound in vivo gene therapy studies. Hum Gene Ther Methods, 2015; 26(3):103–105; doi: 10.1089/hgtb.2015.082
43.
LimberisMP, WilsonJM. Adeno-associated virus serotype 9 vectors transduce murine alveolar and nasal epithelia and can be readministered. Proc Natl Acad Sci U S A, 2006; 103(35):12993–12998; doi: 10.1073/pnas.0601433103
44.
HalbertCL, MillerAD, McNamaraS, et al.Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors. Hum Gene Ther, 2006; 17(4):440–447; doi: 10.1089/hum.2006.17.440
45.
QinX, LiH, ZhaoH, et al.Prevalence of neutralizing antibodies against AAV serotypes 2 and 9 in healthy participants from multiple centers across China and patients with DMD/BMD. Hum Gene Ther, 2024; 35(23–24):969–977; doi: 10.1089/hum.2024.079
46.
VermaS, NwosuSN, RazdanR, et al.Seroprevalence of adeno-associated virus neutralizing antibodies in males with duchenne muscular dystrophy. Hum Gene Ther, 2023; 34(9–10):430–438; doi: 10.1089/hum.2022.081
47.
LeborgneC, LatournerieV, BoutinS, et al.Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients. Cell Immunol, 2019; 342:103780; doi: 10.1016/j.cellimm.2018.03.004
48.
van OldenRW, Lo BiancoC, DillyKW, et al.Adeno-associated virus serotype 9 antibodies in neonates and young children: Seroprevalence and kinetics. Mol Ther Methods Clin Dev, 2024; 32(4):101344.
49.
Seker YilmazB, BaruteauJ, RahimAA, et al.Clinical and molecular features of early infantile niemann pick type C disease. Int J Mol Sci, 2020; 21(14):5059; doi: 10.3390/ijms21145059
50.
BernsKI, MuzyczkaN. AAV: An overview of unanswered questions. Hum Gene Ther, 2017; 28(4):308–313; doi: 10.1089/hum.2017.048
51.
ChenCL, JensenRL, SchneppBC, et al.Molecular characterization of adeno-associated viruses infecting children. J Virol, 2005; 79(23):14781–14792; doi: 10.1128/JVI.79.23.14781-14792.2005
52.
Staretz-ChachamO, AviramM, MoragI, et al.Pulmonary involvement in Niemann-Pick C type 1. Eur J Pediatr, 2018; 177(11):1609–1615; doi: 10.1007/s00431-018-3219-6
53.
WalterfangM, ChienYH, ImrieJ, et al.Dysphagia as a risk factor for mortality in Niemann-Pick disease type C: Systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis, 2012; 7:76; doi: 10.1186/1750-1172-7-76
54.
GuoP, ZhangJ, ChrzanowskiM, et al.Rapid AAV-neutralizing antibody determination with a cell-binding assay. Mol Ther Methods Clin Dev, 2019; 13:40–46; doi: 10.1016/j.omtm.2018.11.007
55.
WeberT. Anti-AAV antibodies in AAV gene therapy: Current challenges and possible solutions. Front Immunol, 2021; 12:658399; doi: 10.3389/fimmu.2021.658399
56.
MendellJR, ConnollyAM, LehmanKJ, et al.Testing preexisting antibodies prior to AAV gene transfer therapy: Rationale, lessons and future considerations. Mol Ther Methods Clin Dev, 2022; 25:74–83; doi: 10.1016/j.omtm.2022.02.011
57.
Louis JeuneV, JoergensenJA, HajjarRJ, et al.Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods, 2013; 24(2):59–67; doi: 10.1089/hgtb.2012.243
58.
KruzikA, FetahagicD, HartliebB, et al.Prevalence of anti-adeno-associated virus immune responses in international cohorts of healthy donors. Mol Ther Methods Clin Dev, 2019; 14:126–133; doi: 10.1016/j.omtm.2019.05.014
59.
CalcedoR, WilsonJM. Humoral immune response to AAV. Front Immunol, 2013; 4:341; doi: 10.3389/fimmu.2013.00341
60.
WangL, CalcedoR, BellP, et al.Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther, 2011; 22(11):1389–1401; doi: 10.1089/hum.2011.031
61.
HurlbutGD, ZieglerRJ, NietupskiJB, et al.Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy. Mol Ther, 2010; 18(11):1983–1994; doi: 10.1038/mt.2010.175
62.
HaurigotV, MarcóS, RiberaA, et al.Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest, 2013; 123(8):3254–3271; doi: 10.1172/JCI66778
63.
GraySJ, Nagabhushan KalburgiS, McCownTJ, et al.Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. Gene Ther, 2013; 20(4):450–459; doi: 10.1038/gt.2012.101
64.
HarkinsAL, AmbegaokarPP, KeelerAM. Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference? Neurotherapeutics, 2024; 21(4):e00435; doi: 10.1016/j.neurot.2024.e00435
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
